Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 297

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 297
---
 to June 30, 2024, and approximately $ 750 for the period July 1, 2024, to June 30, 2025. As a result of receiving the grant, the REM-001, 15-patient clinical trial will be re-started. The grant is expended to the Company as a reimbursement of expenditures incurred. During the three and six months ended December 31, 2023, the Company received $ 197 (2022 - nil ) and $ 210 (2022 - nil ), respectively, for grants received against research and development expenditures in the period.

The grant is subject to various performance conditions and funding risk where the financial conditions of the NIH may change from time to time. The Company recognizes the grant only to the extent there is reasonable assurance the grant will be funded to the Company.

F-5 6

Kintara Therapeutics, Inc. Notes to Condensed Consolidated Interim Financial Statements (Unaudited) December 31, 2023 (expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted)

| 5 | Property and equipment, net |

| Balance, June 30, 2023     |     | $(thousands) | 709 |   |
|:---------------------------|:----|:-------------|----:|:--|
| Additions                  |     |              |  20 |   |
| Depreciation               |     |              | (30 | ) |
| Balance, December 31, 2023 |     |              | 699 |   |

At December 31, 2023, the total capitalized cost of property and equipment was $ 879 (June 30, 2023 - $ 859 ), of which $ 699 is not in use. The Company has recognized $ 30 in depreciation expense, respectively, for each of the six months ended December 31, 2023, and 2022, on equipment in use.

| 6 | Related party transactions |

Valent Technologies, LLC Agreements

On November 20, 2023, Dr. Brown was terminated from his position as the Company’s Chief Scientific Officer as a result of cost-cutting measures adopted by the Company; he remains a consultant to the Company. Dr. Brown is a principal of Valent Technologies, LLC (“Valent”) and as a result Valent is a related party to the Company.

On September 12, 2010, the Company